CTH 401
Alternative Names: CTH-401Latest Information Update: 07 Oct 2024
At a glance
- Originator Cartherics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer; Solid tumours
Most Recent Events
- 30 Sep 2024 Cartherics plans the first clinical trial for Ovarian cancer in 2025 (Parenteral)
- 24 Jan 2023 CTH 401 is available for licensing as of 24 Jan 2023. https://cartherics.com/the-pipeline/ (Cartherics pipeline, January 2023)
- 24 Jan 2023 Preclinical trials in Ovarian cancer in Australia (Parenteral) (Cartherics pipeline, January 2023)